Alexandre Selmani alleged that GlaxoSmithKline fired him for raising concerns about the accuracy of clinical data used to tout the effectiveness of its NiQuitin smoking-cessation product (in the United States, Glaxo markets the product as Nicoderm). The company submitted the data for publication in a pharmacological journal in April 2014. Selmani claimed the company began retaliating against him in December 2012, several months after he began voicing concerns about problems with the statistical methodology in research conducted on smoking reduction and cessation. Glaxo fired Selmani in October 2015. Selmani also claimed that Glaxo engaged in an illegal, deceptive marketing program worldwide to promote NiQuitin by asserting, without justification, that NiQuitin was superior to existing nicotine treatment. The case settled in 2018.